Cargando…
Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis
BACKGROUND: Immune checkpoint inhibitors have revolutionized the treatment of malignancies. However, disproportionate enrollment among races and ethnicities places the generalizability of global trial results in doubt. METHODS: In this systematic review, phase 3 randomized controlled trials investig...
Autores principales: | Peng, Shang‐Hsuan, Lin, Ching‐Hung, Chen, I‐Chun, Shen, Ying‐Chun, Chang, Dwan‐Ying, Chen, Tom Wei‐Wu, Huang, Shu‐Min, Hu, Fu‐Chang, Lu, Yen‐Shen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587960/ https://www.ncbi.nlm.nih.gov/pubmed/37737544 http://dx.doi.org/10.1002/cam4.6563 |
Ejemplares similares
-
Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations
por: Huang, Lien-Hung, et al.
Publicado: (2021) -
Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017) -
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
por: Chen, I-Chun, et al.
Publicado: (2021) -
High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country
por: Lin, Ching-Hung, et al.
Publicado: (2015) -
Association of ABCG2 rs2231142 Allele and BMI With Hyperuricemia in an East Asian Population
por: Chen, Yen-Ju, et al.
Publicado: (2021)